First Tracks Biotherapeutics

Biotechnology
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases. Headquartered in San Diego, California, the company was spun off from AnaptysBio in April 2026 to independently advance its immunology pipeline. Its lead clinical programs include ANB033, a CD122 antagonist in Phase 1b development for celiac disease and eosinophilic esophagitis, and rosnilimab, a pathogenic T cell depleter that has completed Phase 2b trials for rheumatoid arthritis. The company's pipeline also features ANB101, a BDCA2 modulator in Phase 1a testing. First Tracks Biotherapeutics operates as a single business segment dedicated to the research and development of protein-based therapeutics.

$1.9B

Market Cap • 11/19/2026

NASDAQ

Listing Exchange

Flag of United States

United States

Country